Mégraud F
Laboratoire de Bactériologie, Hôpital Pellegrin, Place Amélie Raba-Léon, 33076 Bordeaux cedex, France.
Int J Antimicrob Agents. 2000 Dec;16(4):507-9. doi: 10.1016/s0924-8579(00)00286-7.
Increased resistance to clarithomycin and metronidazole, the two main antibiotics used to treat Helicobacter pylori infection, has led to a search for alternatives to the proton pump inhibitor based triple therapies commonly used. The main rescuse therapy is a bismuth-based quadruple therapy. However, triple therapies with tetracycline and metronidazole or amoxicillin and metronidazole can be considered in the case of clarithomycin resistance. They can also be used in the case of metronidazole resistance by increasing the dose and duration of metronidazole. The only therapy without clarithomycin and metronidazole includes rifabutin and amoxicillin. Dual therapies with amoxicillin and a proton pump inhibitor at high dose can also be used.
用于治疗幽门螺杆菌感染的两种主要抗生素——克拉霉素和甲硝唑的耐药性增加,促使人们寻找常用的基于质子泵抑制剂的三联疗法的替代方案。主要的补救疗法是基于铋剂的四联疗法。然而,在克拉霉素耐药的情况下,可以考虑使用四环素和甲硝唑或阿莫西林和甲硝唑的三联疗法。在甲硝唑耐药的情况下,也可以通过增加甲硝唑的剂量和疗程来使用这些疗法。唯一不含克拉霉素和甲硝唑的疗法包括利福布汀和阿莫西林。高剂量阿莫西林和质子泵抑制剂的双联疗法也可以使用。